UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of July 2015
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
14 Einstein St.
Ness Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No þ
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
On July 2, 2015, Biondvax Pharmaceuticals Ltd. issued a press release announcing that BiondVax will close trading on NASDAQ on July 10, 2015 and the launch of its new investor relations website. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
2 |
Exhibit Index
Exhibit No. | Description | |
99.1 | Press Release, dated July 2, 2015 |
3 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BiondVax Pharmaceuticals Ltd. | ||
Date: July 6, 2015 | By: | /s/ Ron Babecoff |
Ron Babecoff | ||
Chief Executive Officer |
4
Exhibit 99.1
BiondVax to Close Trading on NASDAQ on July 10, 2015
BiondVax launches a new investor relations website (www.biondvax.com) providing international investors with comprehensive information about the Company, progress and its strategy
Ness Ziona, Israel – July 2, 2015 – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. This event will be the culmination of a week of meetings as part of a non-deal roadshow with US-based institutional investors and financial analysts.
In addition, BiondVax today announced the launch of its new investor relations website, which can be found at www.biondvax.com.
Institutional investors or analysts interested in meeting with BiondVax management in New York or wishing to attend the market closing event should contact the Company’s investor relations team.
Ron Babecoff, BiondVax’s President and CEO, commented, “We are very much looking forward to launching our investor relations operations in the US. The closing event at the NASDAQ is an excellent starting point and the culmination of a long and an important process for us, of listing our shares in the United States, and by that making ourselves accessible to the US capital market.”
About BiondVax Pharmaceuticals Ltd
BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax’s technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.
For further information, please contact:
Company Contact Dr Limor Chen, Director of BD limor.c@biondvax.com
|
Investor Relations Contact GK Investor Relations Kenny Green, Partner +1 646 201 9246 biondvax@gkir.com
|
ZO(;1K>.(3)$JPA6)+;=K'.<'>17=@*\*4:DY M[Z6Z>IE43DU%'F'_``14^#WB7]E#]@'4KGQUI5_X8%]K&J>*+;1KPD7&BV#J MC)%(&"E6^220@@',C%N2:^(?A5\1OVBOV/\`]@P?M$^&?&?A+3?!?B_QD^LO MX-?15N+S6WN;P6NY[F1"RLR0#:L3*`IW;B>*_7?]K/X/ZY\=/V:O&?@OPWK, M/AW5?%&ES:9'J,T+RK:K,-DC;58,3Y9<#!ZD=J^>?VB/^"86N?%O]EKX$_"C M3?%.G:5H'PNO-)N-:S8R/_;0LXTB"H%8!=W[USNSR1FO0PF,IR:P>0^6K;A]TDYZ'WO_`(*)_L::Y^V+\*?"^G^&?$=KX2\2^"?$UCXJ MT>]NK`WMNUS;"0I%+&&7]WN=6R#P8UX(KD?V?_V$_B9X6_;3;XU_$?XCZ1XO MU6_\,3Z`^C:=H;V%CI`>>WF06I::1MO[A@Q?YFWD\9-887V$:#E*U]?7;0;E M4YE;8U?^"DO[2_COX*6/PR\,_#'^SF\?_$CQ1'H]B;^(-:B)8B\[R\$B-058 ME1NP#CWZK]F#PG\7_A-\-/%UY\9?B-HWCK5)9WOM/ETS18].MM,MA",QA`H+ M_O?,.7+$KM)(R15;XK?LAZU\4/V^OAA\5)M>LT\+_#72]0BMM$:T=II[ZZCE MA>?S,[54(\>!C.5)!Z5ZE\:_A_J/Q#^"WBSPWI%[%INI:YHMWI]I>S*SI;32 MPO&DK`' >WR78NSU;/S`N/\`@H/^TM=_L$:E M^TO9^.?#-OX6T?5396?AB30(GFUD?V@EG^\FV#`#LWRQ%6V1YSDXKW[X-?M" M_M!_#/\`X*/^`_AQ\3/$?A?Q1H_Q'\+W^O7&GZ5IJVT?ADPG*>7)L$LBA@(B M9&.[?G`.*V/^'5-_;_L8_`GX-6?B:Q70?AKXDL/$'B1Y=/D_XJ!8)I+B:%$S M\@DEF<_-GA1UQ7JGAS]C[6K3_@HSXD^-FIZ]9WNE7/A*+PIHND):.LNG)YT4 M\LC2$[6+2*WW0,*0#G!SZ4\1@^6<%&/VK>ZK]%'6V_4S4*FCN<_^U[^U1X\D M_:7\*_`GX40Z=8^,O$VC3>(-1\0:A']HMO#MA')Y?F>3@[W:0!`#@9D0^M :W60W3$1*N0=\& M,Y^[U[UK_M#?L-?%'4/VTW^+WPH^('A[PQJ&N^%?^$5UF'7="?4U@B$BNMU; M!'0>:"J81R%)0Y#!B*[7_@G3^QAJO[$WPDU_PSJWB<>,+S5_$U]KC:N]HUO< M7:W'E\S!G?,H93DYY&*XJGL8X*\; 3?$GX_\`QH_;0^.' MCSP3\!?%?ASX;:5\+9UTS5O$>JZ6FJSWU^Y<>7;P,A4(GEL&8XZC&>WM?C/X MV:]^QK^QH/%/Q/U*U\6^*/#]G%'J=QI\0M(=2NI'"*R)P$3+#.%!PI(':O#; M+_@G3\:?@'\:/BAK/P<^+'A[0M`^+>JR:SJ,>O\`AIM1O?#UR[-F2Q*2".0X M8@>>A`7&03S7OG[;O[(%K^VU^RCKOPQU#7-3T0:TL#1:M;1!I[66*1)$?:V` M02F&&02K-@@X-.NJ'/32MR:;;^=WN$74ZGYQ_P##XGXJ:O\`M!?!Z'PC\3/! MWQ`G^(VN6T6H^!-&T!I%TBSF=`=]X8PPEC63YL2$+L9FRH+#[R_:^_:%\3^! M/VDO@#\.O!]^MC=?$37YY-5\RUCE$FEV5N;BYB(=249U4JK#!!JE^Q%^R7\3 M_@5XD\WQOKGPSO-+T_2!I-G#X7\*_P!E7.J2!H]M]>S%V8S;(V&Q,)F4GD@8 M@_:Y_8P^(/Q/_:N^'OQB^&WBWP_H>O\`@>RN-,_LWQ%I$M]I]S%,LRM*!%-$ MZOB5AC %/VH]>\;?\%3/%'PNM+Q M1X1\%^!XM1O[8P(6?4)[B$Q.),;P!"[C&<'/3@&OG3_@H)J_Q4^._P#P5-^' MGPF\`^,-*\,77AWP_)XWL[Z\TQ;Z&QE7S(&W0,2)7+"-E)!V;EQR37M?[`G_ M``3T\8_LQ_'_`.+7Q%\?>.[;X@>(OB5-;;+B#3FL5LHXGF8J$:1\*?,3"KP- MA%5/C)^PC\5KC_@H._QO^'7CKPQHZ:IX>B\-ZA8ZSHCWLMK;+-#)(;9EE1=[ M^2F"XPNYN":JC*A3Q$N1JRA97ZRMJ_F5)MQU1ZG\:]7\=?!C]@?Q#J.H>)-, MU'QOX3\)37^IZW+IJ+:WT]M;F2XD%NORJ)-CX3&!N`->=?\`!.+XEW7PS_X) M2>$_'_C&STFS:/P_<^)[JUT32;;2K=('>6XB6.W@2.)7,)C!(`RV3WKU/]NK M]G[7_P!J3]D_Q=\/O#NN6_AK4?%=O'8MJ$]M).D4)F0S#8K`_-&'7KC#5H^/ MOV9--\;_`+)>J?"5)[O3-%OO#9\.17%NJ^=:Q>3Y*.H(P64`,`>.`#WKAC.F M\.HU/BW;_`((]5+W4?-?P`\5_M/?MCWW@_P"+>A_$#P5X(^%^NW\5Z/"+ MZ*+V[O=(6?:PDNFCRDTD:%DV''[P9V]O5?VY_P!L+6?@IXJ\!_#;P+9VEU\1 MOBK?/8:1 \$^OC]\:M?_X**?&?X5_$7QMIWC#1?AUI M.GO'/;:)!I\ '-6\::C"&^4JP:VA;`_B$XAQD]*[G]@7]@'Q;^RG\>/B]X]\8^.++QWJWQ7 MFT^ZFE@TEK`V4L`G+JJF5QY69]J`'(6/G)-=CHO[).M:#_P4*UWXS1:Y9W>E M:[X5M_#CZ7-8M]JL3#)YF89MX78[!2P*DYZ$54ZM&.(E.G;2&FF\FK/]2??E M!)GG?_!8C]N_7O\`@G_\`=&\0>'[79<:UJJV,^J-:?:8=/\`D+@.F",R;7"Y M_NMZ5M?\$Q?'WQ(^+'@+5?%GBWXM^#_B[X2UYX9?#5]HND#3IK7"L9X;B,*F MUU;:NQEWC!W$'BNQ_:K^%7QF\:^(;.?X;^)?AS!I'V8P7NA>+_#T^H6=U+YF M_P`_?%*K;EPH"XQQG/:L;_@G?^P8W[$'AWQHU_KH\1^(?B%KLWB'6);33UT_ M3;>>0G,-K:JS".)>< */'<_QD M_P"#A#PUX:@D !M"O/&T*V"6^I^%YK^2SLEV%8MPF4%MT:DL`/NJ.`. M8R[DYYJ32;5E?8=235K'W4[,EL0F-^."3@9YK\V/^"9_AOXP_M#_`+8/Q`^- M3?$;1/\`A&(/$,_@W5[)=%C>;7X=/M\0R0R9)MD,MPK%5Z^5SFONKX+^"_'M MC\%6TGXB>*+#Q!XMN1.EQJVD:;_9\**Y81^5$2Q4JA7.2 AQ7@O\`P3G_ M`&(_BS^Q#->^%=4\<>$O$WPZAN+V]M4MM"EM-7N;B=DV/+*TK1A55&X4%LD9 M8BJP_+3I5:=TY;?YV'*# 9::'IZ3>5N\L*V^0MP%(Y++T&37AG[!?@WXB>,O^"RGQAU/XC>*+'Q;J/P MJ\':?X9CO[*S^R6\K7QBNU*QC`5U6.1&]R:]L_:/_8=^)>J_MM:7\8OER(Z.,(-N5&8@2?F;/2_\$^?V*?$? M[)<7Q&U+QCXN3QWXP^(7B*36K_68[-K3S(Q#$D,/ELSXV-YI&"5`?'88Z8U* M-/"\T&KN-O.[>K^XRM.3M+8^D5DQCGN.]2X/K7EZ^`/B&W[5B>(_^$SLQ\-4 MT-K,^%_[,_?-?F16%S]HZX"!ACISTXS7J->,XJ-K,W3OL(*6BBD,****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** 7`"BBB@`HHHH`****`"BBB@`HHHH`_]D_ ` end